Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

Blood (2014) 124 (3): 420–425.

https://doi.org/10.1182/blood-2013-12-538975

Published: 2014

Includes: Supplemental data

Journal Articles

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

Blood (2013) 121 (18): 3650–3657.

https://doi.org/10.1182/blood-2012-10-458695

Published: 2013

Includes: Supplemental data

Journal Articles

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Blood (2011) 118 (21): 2445.

https://doi.org/10.1182/blood.V118.21.2445.2445

Published: 2011

Journal Articles

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Blood (2011) 118 (21): 3521.

https://doi.org/10.1182/blood.V118.21.3521.3521

Published: 2011

Journal Articles

Effect of FCGR2A and FCGR3A variants on CLL outcome

Blood (2010) 116 (20): 4212–4222.

https://doi.org/10.1182/blood-2010-03-272765

Published: 2010

Journal Articles

PI3K Signaling Pathway Activation Predicts Class I PI3K Inhibitor GDC-0941 Sensitivity in AML.

Xiaoju Max Ma, PhD, Changchun Du, BM, BS, Laura Sun, Xiaoyan Shi, Ph.D, Lori Friedman, David Dornan, Ph.D, Allen J. Ebens, PhD

Blood (2009) 114 (22): 1057.

https://doi.org/10.1182/blood.V114.22.1057.1057

Published: 2009

Journal Articles

Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone.

Daniel O. Persky, MD, David Dornan, Ph.D, Bryan H Goldman, MS, Rita M. Braziel, MD, Richard I Fisher, MD, Michael LeBlanc, PhD, David G. Maloney, MD, PhD, Thomas P. Miller, MD, Oliver W. Press, MD, PhD, Lisa M. Rimsza, MD

Blood (2009) 114 (22): 111.

https://doi.org/10.1182/blood.V114.22.111.111

Published: 2009

Journal Articles

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

David Dornan, Ph.D, Olivia Spleiss, Ph.D, Ru-Fang T Yeh, PhD, Guillemette Duchateau-Nguyen, PhD, Tadeusz Robak, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Celigny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Viktor A Rossiev, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Christian H. Geisler, MD, DMSc, Marco Montillo, MD, Michael K. Wenger, MD, Martin Weisser, MD

Blood (2009) 114 (22): 2338.

https://doi.org/10.1182/blood.V114.22.2338.2338

Published: 2009

Journal Articles

CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma.

Blood (2009) 114 (22): 2721.

https://doi.org/10.1182/blood.V114.22.2721.2721

Published: 2009

Journal Articles

Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

Blood (2009) 114 (13): 2721–2729.

https://doi.org/10.1182/blood-2009-02-205500

Published: 2009

Includes: Supplemental data

Journal Articles

Identification of a Diagnostic Gene Signature for SGN-40, Anti-CD40 Monoclonal Antibody, in Pre-Clinical NHL Models and the Role of FAS in SGN-40 Mediated Apoptosis.

Xiaoyan Shi, Ph.D, Bart Burington, Ph.D, Tom Januario, Jeffrey T Lau, Shang-Fan Yu, Allen Ebens, Ph.D, David Dornan, Ph.D

Blood (2008) 112 (11): 1593.

https://doi.org/10.1182/blood.V112.11.1593.1593

Published: 2008

Journal Articles

Development and Therapeutic Potential of an Anti-CD79b Antibody-Drug Conjugate, Anti-CD79b-Vc-MMAE, for the Treatment of Non-Hodgkin’s Lymphoma

Blood (2008) 112 (11): 2618.

https://doi.org/10.1182/blood.V112.11.2618.2618

Published: 2008

Journal Articles

A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma.

Ranjana Advani, MD, Sven De Vos, MD, PhD, Stephen M. Ansell, MD, Brad Kahl, MD, Bruce D. Cheson, MD, Nancy L. Bartlett, MD, Richard R. Furman, MD, Jane N. Winter, MD, Henry Kaplan, MD, David Dornan, PhD, Nancy Whiting, PharmD, BCOP, Jonathan Drachman, MD, Andres Forero-Torres, MD

Blood (2008) 112 (11): 1000.

https://doi.org/10.1182/blood.V112.11.1000.1000

Published: 2008

NARROW

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Effect of FCGR2A and FCGR3A variants on CLL outcome

PI3K Signaling Pathway Activation Predicts Class I PI3K Inhibitor GDC-0941 Sensitivity in AML.

Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone.

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma.

Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

Identification of a Diagnostic Gene Signature for SGN-40, Anti-CD40 Monoclonal Antibody, in Pre-Clinical NHL Models and the Role of FAS in SGN-40 Mediated Apoptosis.

Development and Therapeutic Potential of an Anti-CD79b Antibody-Drug Conjugate, Anti-CD79b-Vc-MMAE, for the Treatment of Non-Hodgkin’s Lymphoma

A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only